Wenting Yu

Counsel

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Wenting Yu is a corporate transactional lawyer specializing in securities offerings, venture financings, mergers and acquisitions and other corporate transactions. She regularly assists startup, midsize, and large companies across a variety of industries. Wenting provides her clients with innovative legal approaches to complex transactions. She is communicative and works diligently to produce successful results for her clients so that she can position them for success.

Languages

  • Mandarin Chinese

Admissions

Bar Admissions

  • California
  • New York

Education

  • Washington University School of Law, J.D., Dean's List
  • Washington University School of Law, LL.M., with honors
  • Shanghai Normal University, LL.B., with honors

Professional Activities

Extern

  • Office of Compliance Inspections and Examinations, Securities and Exchange Commission

Co-author

  • "Joint Ventures in Emerging Markets: the Keys to Success" (Financier Worldwide, June 2012)

Mergers and Acquisitions

  • Tricentis, a Vienna, Austria-based software company, in its sale to Insight Venture Partners
  • Shanghai Haohai Biological Technology in its acquisition of the Aaren Scientific hydrophilic business of Carl Zeiss
  • Cambridge Industries Group Shanghai in its acquisition of the long-range optical subassembly product line of MACOM Japan
  • Pharmaron in its acquisition of a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc., a leading provider of moderate and highly complex Phase I/II clinical development services for the life sciences sector
  • Pharmaron in its acquisition of Quotient Bioresearch Group Limited
  • Pharmaron in its acquisition of Xceleron Inc, a US-based globally leading Accelerator Mass Spectrometry (AMS) specialist for life sciences

Venture Capital / Private Equity Financings

  • eHi Car Services Limited (NYSE: EHIC) in a Regulation S private offering of US$400 million Senior Unsecured Notes
  • JHL Biotech, Inc. in its voluntary delisting from the Taipei Stock Exchange followed by a $106 million convertible note financing
  • Hua Medicine in its Series D and Series E financing, with a combined capital raise of US$117.4 million
  • Gladly in its US$50 million Series D financing and US$36 million Series C financing
  • Adagene in its $50 million Series C financing
  • Optovue, Inc. in its $37 million Series C and Series D financings
  • Steamboat Ventures in the sale to NewQuest of its investments in various portfolio companies
  • Virtus Inspire Ventures in its investments in Apexigen, Embolx and Envive
  • City Energy Holdings Limited in of its investment in Edetek Inc.